ÂÜÀòÂÒÂ×

Colin O'Bryan is an experienced professional in the field of process chemistry, currently serving as the Associate Director of Drug Substance, CMC at Crinetics Pharmaceuticals since September 2022. Prior to this role, Colin held positions at Nura Bio as Senior Manager and Process Chemistry Lead from September 2021 to August 2022, and at Takeda Development Center Americas, Inc. from April 2006 to September 2021, where responsibilities included enabling pre-IND and Phase I drug substance manufacture and leading external research partnerships. Colin's earlier experience includes positions at Celera Genomics and Pharm-Eco Laboratories. Colin holds a Bachelor of Science degree in Chemistry from Roger Williams University.